| scholarly article | Q13442814 |
| P2093 | author name string | A. S. Troupin | |
| P. Friel | |||
| P2860 | cites work | Aspects of the pharmacology of phenytoin (dilantin) and phenobarbital relevant to their dosage in the treatment of epilepsy | Q79313528 |
| Plasma levels of anticonvulsants | Q39873181 | ||
| Diphenylhydantoin concentrations in saliva | Q43972399 | ||
| Binding of 5,5-diphenylhydantoin and its major metabolite to human and rat plasma proteins | Q44883556 | ||
| Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease | Q47886443 | ||
| The effect of certain drugs on the plasma protein binding of phenytoin. | Q52728947 | ||
| Serum Concentrations of Free Diphenylhydantoin and their Relationship To Clinical Intoxication | Q54312303 | ||
| Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution | Q68749158 | ||
| Plasma protein binding of diphenylhydantoin in patients with epilepsy. Agreement between the unbound fraction in plasma and the concentration in the cerebrospinal fluid | Q70347852 | ||
| Micromethod for the Determination of Diphenylhydantoin in Plasma and Cerebrospinal Fluid—A Comparison Between a Gas Chromatographic and a Spectrophotometric Method | Q70403010 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neurology | Q83042 |
| saliva | Q155925 | ||
| P304 | page(s) | 223-227 | |
| P577 | publication date | 1975-06-01 | |
| P1433 | published in | Epilepsia | Q5382969 |
| P1476 | title | Anticonvulsant level in saliva, serum, and cerebrospinal fluid | |
| Anticonvulsant Level in Saliva, Serum, and Cerebrospinal Fluid | |||
| P478 | volume | 16 |
| Q70620140 | A comparison of plasma and saliva levels of carbamazepine and phenytoin as monotherapy |
| Q50016064 | A descriptive systematic review of salivary TDM in neonates and infants |
| Q69565115 | A micromethod for the estimation of free levels of anticonvulsant drugs in serum |
| Q40142216 | Anticonvulsant drugs. An update |
| Q40265358 | Antiepileptic therapeutic drug monitoring. |
| Q71795312 | Automated analysis of free and total concentrations of three antiepileptic drugs in plasma with on-line dialysis and high-performance liquid chromatography |
| Q73546079 | Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat |
| Q34987488 | Carbamazepine dose-frequency requirement in children |
| Q38627226 | Carbamazepine toxicity and poisoning. Incidence, clinical features and management |
| Q39291243 | Clinical pharmacology of mephenytoin and ethotoin |
| Q67470348 | Comparison of phenytoin determinations in plasma, plasma dialysate and saliva for control of antiepileptic therapy in children |
| Q67380294 | Diphenylhydantoin, Phenobarbital, and Primidone in Saliva, Plasma, and Cerebrospinal Fluid |
| Q40828077 | Disposition of valproic acid in man |
| Q66694661 | Drug formulation and salivary phenytoin measurements |
| Q51878818 | Entry of diazepam and its major matabolite into cerebrospinal fluid. |
| Q39220508 | Excretion of antiepileptic drugs in sweat |
| Q66923351 | Flow-Dependent Salivary Primidone Levels in Epileptic Children |
| Q39754383 | Free drug concentration monitoring in clinical practice. Rationale and current status |
| Q66694660 | Hand-mirror-cell leukaemia |
| Q40764712 | Implications of Measuring Anticonvulsant Blood Levels in Epilepsy |
| Q36748917 | Interpretation of oral fluid tests for drugs of abuse |
| Q67796992 | Management of seizure disorders with anticonvulsant drugs: current concepts |
| Q41735368 | Monitoring saliva anticonvulsant levels in children |
| Q34745264 | Phenytoin-valproate interaction: importance of saliva monitoring in epilepsy |
| Q40640453 | Plasma level monitoring of anticonvulsants |
| Q43241001 | Rapid and sensitive high-pressure liquid chromatographic method for monitoring carbamazepine levels in serum |
| Q55184696 | Saliva carbamazepine levels in children |
| Q34448908 | Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients |
| Q66959443 | Tears as the Best Practical Indicator of the Unbound Fraction of an Anticonvulsant Drug |
| Q39239700 | The Monitoring of Saliva Drug Levels: Psychiatric Applications |
| Q38243033 | Therapeutic Drug Monitoring in Saliva |
| Q33700135 | Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants |
| Q35653966 | Therapeutic drug monitoring in saliva. An update |
| Q38018025 | Therapeutic drug monitoring of phenytoin. Rationale and current status |
| Q67674799 | Use of saliva in monitoring carbamazepine medication in epileptic children |
| Q34448902 | Valproic acid fails to displace phenobarbitone and carbamazepine from plasma protein binding sites in epileptic patients |
Search more.